Dybly, based in Basel, Switzerland, is a renowned brand that specializes in developing pharmaceutical products for patients with inflammatory and fibrotic diseases. With a focus on innovation and patient well-being, Dybly has created a range of groundbreaking solutions to address conditions such as atherosclerosis, stroke, intermittent claudication, and peripheral vascular disease. Dybly's expertise lies in lipid management and cardiovascular health, offering treatments that target HDL, LDL, and triglycerides for effective prevention and cure of these conditions.

Their dedication to research and development has led to partnerships with industry leaders such as Resverlogix and Esperion. With a strong commitment to improving patients' quality of life, Dybly's products are designed to combat inflammation, aging, and fibrosis, making them an ideal choice for those affected by senescence-associated diseases like idiopathic pulmonary fibrosis and radiation-induced fibrosis. In 2021, Dybly's exceptional programs found a new home at Worg Pharmaceuticals, ensuring that their groundbreaking research and life-changing products continue to make a difference in the lives of patients worldwide